I don't see any a-priori issues with mRNA safety - mRNA is by design an ephemeral product with no chance of self-replication. Its long term efficacy on the oth

I don't see any a-priori issues with mRNA safety - mRNA is by design an ephemeral product with no chance of self-replication. Its long term efficacy on the other hand is yet unknown and the supply chain issues are significant (it's a result of mRNA being an ephemeral cellular product being stored artificially). Of course if you made an mRNA virus to produce some sort of toxic cellular protein then safety would be an issue - which is what the phase 1 and 2 trials are about. Phase 4 is about finding the one in a million adverse reactions.